ArticleCells2023

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC).

Kostas A Papavassiliou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.